<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diphenhydramine (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diphenhydramine (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Diphenhydramine (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9109" href="/d/html/9109.html" rel="external">see "Diphenhydramine (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="11659" href="/d/html/11659.html" rel="external">see "Diphenhydramine (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8082074"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aler-Dryl [OTC] [DSC];</li>
<li>Allergy Childrens [OTC];</li>
<li>Allergy Relief Childrens [OTC];</li>
<li>Allergy Relief [OTC];</li>
<li>Anti-Hist Allergy [OTC];</li>
<li>Aurodryl Allergy Childrens [OTC] [DSC];</li>
<li>Banophen [OTC];</li>
<li>Benadryl Allergy Childrens [OTC];</li>
<li>Benadryl Allergy Extra Str [OTC];</li>
<li>Benadryl Allergy Ultratabs [OTC];</li>
<li>Benadryl Allergy [OTC];</li>
<li>Complete Allergy Relief [OTC];</li>
<li>Di-Phen [DSC];</li>
<li>Diphen [DSC];</li>
<li>Diphen [OTC];</li>
<li>Diphenhist [OTC] [DSC];</li>
<li>FT Allergy Relief Childrens [OTC];</li>
<li>FT Allergy Relief [OTC];</li>
<li>FT Nighttime Sleep Aid [OTC];</li>
<li>FT Sleep-Aid Maximum Strength [OTC];</li>
<li>Geri-Dryl [OTC];</li>
<li>GoodSense Allergy Relief [OTC];</li>
<li>GoodSense Sleep Aid [OTC];</li>
<li>GoodSense Sleep-Aid Max Str [OTC];</li>
<li>M-Dryl [OTC];</li>
<li>Naramin [OTC];</li>
<li>Nighttime Sleep Aid [OTC];</li>
<li>Nytol Maximum Strength [OTC] [DSC];</li>
<li>Nytol [OTC] [DSC];</li>
<li>Ormir [OTC] [DSC];</li>
<li>PediaCare Childrens Allergy [OTC];</li>
<li>PediaClear Cough Childrens [OTC] [DSC];</li>
<li>Pharbedryl [OTC];</li>
<li>Siladryl Allergy [OTC];</li>
<li>Simply Sleep [OTC];</li>
<li>Sleep Tabs [OTC];</li>
<li>Total Allergy Medicine [OTC];</li>
<li>Total Allergy [OTC];</li>
<li>Vanamine PD [OTC] [DSC];</li>
<li>ZzzQuil [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871058"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Diphenist</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10824348"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Drug-induced Dystonic Reactions</span>;</li>
<li>
<span class="list-set-name">Antidote, Hypersensitivity Reactions</span>;</li>
<li>
<span class="list-set-name">Antihistamine</span>;</li>
<li>
<span class="list-set-name">Sedative</span></li></ul></div>
<div class="block dop drugH1Div" id="F8082169"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Dosage form information:</b> Oral solutions are available in 2 concentrations (2.5 mg/mL [12.5 mg per 5 mL] and 1.67 mg/mL [50 mg per 30 mL] [eg, ZzzQuil]); take precautions to verify product selection and avoid confusion between the different concentrations. Dose should be clearly presented as "<b>mg</b>" instead of "mL."</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Many OTC cough/cold/allergy products contain diphenhydramine; consider all sources of diphenhydramine when evaluating maximum daily doses. Infants and neonates are highly sensitive to depressive effects of diphenhydramine; use is contraindicated in neonates (premature and term); use with extreme caution in infants and young children.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e29653d4-d714-4f73-85b3-2c89433403f5">Allergic rhinitis/rhinoconjunctivitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis/rhinoconjunctivitis (including upper respiratory allergies or hay fever): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to adverse effects (paradoxical agitation/excitation or sedation), first-generation H<sub>1</sub> antihistamines (eg, diphenhydramine) are not recommended as first-line therapy for management of allergic rhinitis in pediatric patients; second-generation minimally sedating antihistamines are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227'])">Ref</a></span>). Infants and neonates are highly sensitive to depressive effects of diphenhydramine; use is contraindicated in neonates (premature and term); use with extreme caution in infants and young children.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing</i>: <b>Note:</b> Although manufacturer labeling allows for every-4-hours dosing, the pharmacokinetics in pediatric patients suggest that a longer dosing interval is adequate; reassess patient's symptoms prior to each dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;6 years: Limited data available: Oral: 6.25 mg every 4 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3962845','lexi-content-ref-Milgrom.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3962845','lexi-content-ref-Milgrom.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 to &lt;12 years: Oral: 12.5 to 25 mg every 4 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3962845','lexi-content-ref-Milgrom.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3962845','lexi-content-ref-Milgrom.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Oral: 25 to 50 mg every 4 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3962845','lexi-content-ref-Milgrom.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3962845','lexi-content-ref-Milgrom.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥9 kg, Children, and Adolescents: Oral: 5 mg/kg/day in equally divided doses every 6 to 8 hours; age-related maximum single doses: &lt;6 years: 6.25 mg/dose; 6 to 11 years: 25 mg/dose; ≥12 years: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3962845','lexi-content-ref-Milgrom.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3962845','lexi-content-ref-Milgrom.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="51a3e279-7bfd-4a16-8052-19a0580f3cee">Anaphylaxis, adjunct to epinephrine</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis, adjunct to epinephrine: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administer epinephrine first when treating anaphylaxis. Do <b>not</b> use diphenhydramine as initial therapy; H<sub>1</sub> antihistamines will <b>not</b> alleviate stridor, shortness of breath, wheezing, GI symptoms, hypotension, or shock and are considered second- or third-line agents in the management of anaphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-32001253','lexi-content-ref-31871244','lexi-content-ref-23268454','lexi-content-ref-26525001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-32001253','lexi-content-ref-31871244','lexi-content-ref-23268454','lexi-content-ref-26525001'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: IV, IM, Oral: 1 mg/kg/dose; maximum dose: 50 mg/dose; may repeat every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-32001253','lexi-content-ref-31871244','lexi-content-ref-23268454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-32001253','lexi-content-ref-31871244','lexi-content-ref-23268454'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IV, IM, Oral: 25 to 50 mg/dose; may repeat every 4 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-32001253','lexi-content-ref-31871244','lexi-content-ref-23268454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-32001253','lexi-content-ref-31871244','lexi-content-ref-23268454'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7248c28-2370-4bda-809e-dd7f736ffd27">Cutaneous disorders with pruritus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous disorders with pruritus (eg, urticaria, atopic dermatitis, other pruritic skin conditions):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>First-generation antihistamines (eg, diphenhydramine) are not recommended as first-line agents for urticaria (acute or chronic) due to risk of adverse reactions; second-generation antihistamines are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31416456','lexi-content-ref-DelPozzoMagana.2017','lexi-content-ref-29336054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31416456','lexi-content-ref-DelPozzoMagana.2017','lexi-content-ref-29336054'])">Ref</a></span>). For atopic dermatitis, diphenhydramine may provide intermittent relief of pruritus and may help with sleep loss associated with the pruritus; however, it does not treat underlying condition and is not a substitute for topical therapy; chronic use is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24813298','lexi-content-ref-34280477']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24813298','lexi-content-ref-34280477'])">Ref</a></span>). Dosing recommendations are based on general dosing range in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥9 kg and Children: Oral: 5 mg/kg/day in equally divided doses administered every 6 to 8 hours as needed; usual age-related single doses: &lt;6 years: 6.25 mg/dose; 6 to 11 years: 25 mg/dose; ≥12 years: 25 to 50 mg/dose; maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3962845','lexi-content-ref-Milgrom.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3962845','lexi-content-ref-Milgrom.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 5 mg/kg/day in equally divided doses administered every 6 to 8 hours as needed; usual dose: 25 to 50 mg/dose; maximum dose: 50 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="674c5055-2d63-4377-95ae-f5fd7f535f34">Extrapyramidal symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extrapyramidal symptoms (EPS) (eg, medication-induced dystonic reactions):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial:</i> IV (preferred), IM, Oral: 1 to 2 mg/kg/dose; maximum dose: 50 mg/dose; may repeat in 30 minutes if no response. Oral therapy may be considered for home use while medical care is sought (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-8729889','lexi-content-ref-Fuhrman.2017','lexi-content-ref-2870459','lexi-content-ref-23115503','lexi-content-ref-3797269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-8729889','lexi-content-ref-Fuhrman.2017','lexi-content-ref-2870459','lexi-content-ref-23115503','lexi-content-ref-3797269'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Subsequent doses</i> (if needed): IV, Oral: 5 mg/kg/day in equally divided doses administered every 6 to 8 hours for up to 2 to 5 days may be considered to prevent recurrence. Maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23115503','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23115503','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pretreatment:</i> Limited data available: <b>Note:</b> Recommended for use when high-dose metoclopramide is required and should be considered when use of other medications known to have a high risk of EPS (eg, high-dose chlorpromazine or prochlorperazine) are required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4020411','lexi-content-ref-23512831','lexi-content-ref-24512575','lexi-content-ref-21296523','lexi-content-ref-Wolfe.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4020411','lexi-content-ref-23512831','lexi-content-ref-24512575','lexi-content-ref-21296523','lexi-content-ref-Wolfe.2018'])">Ref</a></span>). Diphenhydramine has not been shown to prevent akathisia symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21296523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21296523'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 0.5 to 1 mg/kg/dose concomitantly with high-risk medication; repeat dose may be necessary with continued therapy depending on administered medication. Maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4020411','lexi-content-ref-24512575','lexi-content-ref-21296523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4020411','lexi-content-ref-24512575','lexi-content-ref-21296523'])">Ref</a></span>). Higher doses of 2 mg/kg/dose (maximum dose: 50 mg/dose) have also been reported in children ≥5 years and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26359823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26359823'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b90818fe-3782-45a6-b8c1-7d20f52e3070">Infusion or transfusion reactions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion or transfusion reactions:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Premedication</i> (eg, radiocontrast agents, IVIG, monoclonal antibody therapy, chemotherapy): Limited data available: <b>Note</b>: Use of premedication should be individualized to patient factors and institutional protocols; may be given in combination with acetaminophen, corticosteroids, and/or H<sub>2</sub> antihistamines. For blood products, pretreatment is not routinely recommended because use has not been shown to significantly impact the rate of allergic reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24794886','lexi-content-ref-20556779','lexi-content-ref-33275693','lexi-content-ref-16115137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24794886','lexi-content-ref-20556779','lexi-content-ref-33275693','lexi-content-ref-16115137'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV, Oral: 1 mg/kg/dose administered 30 to 60 minutes prior to infusion; maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28041678','lexi-content-ref-ACR.1','lexi-content-ref-11839657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28041678','lexi-content-ref-ACR.1','lexi-content-ref-11839657'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i> Limited data available: <b>Note: </b>If patient is experiencing anaphylaxis, administer epinephrine first. Do <b>not</b> use diphenhydramine for initial or sole treatment of anaphylaxis because H<sub>1</sub> antihistamines do <b>not</b> relieve upper or lower airway obstruction, hypotension, or shock. Diphenhydramine should be used for symptomatic relief as an adjunct to other appropriate measures (eg, stopping the infusion, reducing the infusion rate).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IV: 1 mg/kg/dose; maximum dose: 50 mg/dose; may repeat every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-ACR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IV, IM, Oral: 25 to 50 mg/dose; may repeat every 4 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-ACR.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae3da13f-4010-4982-8591-e226cd4cf412">Insomnia, occasional</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Insomnia, occasional: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Efficacy results are variable. Evaluation of sleep hygiene and use of nonpharmacologic (ie, behavioral) treatment are preferred; medications may be used as adjunct treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17561616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17561616'])">Ref</a></span>). While diphenhydramine has been shown to improve sleep latency and reduce nighttime awakenings in children 2 to 12 years of age, studies have not supported the use of diphenhydramine to improve sleep in younger children or infants; routine use is not recommended in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27998379','lexi-content-ref-16818836','lexi-content-ref-Russo.1976']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27998379','lexi-content-ref-16818836','lexi-content-ref-Russo.1976'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Limited data are available for children &lt;12 years: Oral: 0.5 to 1 mg/kg administered 30 minutes before bedtime as needed; usual dose: 12.5 to 50 mg/dose; maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24605272','lexi-content-ref-Russo.1976','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24605272','lexi-content-ref-Russo.1976','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03fb9bcc-db9c-46fd-92d3-647d7af01df4">Nausea and vomiting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>General dosing:</i></b> Limited data available: <b>Note:</b> Diphenhydramine may be used for both its antihistamine (causing drowsiness) and antimuscarinic (reducing nausea) effects as adjunct therapy with antiemetics to manage nausea and vomiting associated with various presenting conditions (eg, chemotherapy-induced nausea/vomiting, cyclic vomiting syndrome, migraine, palliative care) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512','lexi-content-ref-30159612','lexi-content-ref-24512575','lexi-content-ref-Wolfe.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512','lexi-content-ref-30159612','lexi-content-ref-24512575','lexi-content-ref-Wolfe.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV, IM, Oral: 0.625 to 1.25 mg/kg/dose every 6 hours; maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2019','lexi-content-ref-30159612','lexi-content-ref-30076469','lexi-content-ref-Wyllie.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2019','lexi-content-ref-30159612','lexi-content-ref-30076469','lexi-content-ref-Wyllie.2016'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Motion sickness:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prophylaxis:</i>
<b>Note: </b>First dose should be administered 30 to 60 minutes before travel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children: Oral: 0.5 to 1 mg/kg/dose every 6 hours during triggering motion; usual dose: 12.5 to 25 mg/dose; maximum dose: 25 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 12.5 to 25 mg every 6 to 8 hours during triggering motion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">IV, IM: 1.25 mg/kg/dose every 6 hours as needed; maximum dose: 50 mg/dose. <b>Note:</b> Usual adult dose: 10 to 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Oral: 5 mg/kg/day in equally divided doses administered every 6 to 8 hours as needed; usual dose: 12.5 to 25 mg/dose; maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c641946f-a396-4b5f-8d9f-53f612145141">Scombroid poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Scombroid (histamine) poisoning:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be useful for patients with uncomfortable symptoms (eg, flushing, burning, rash) but <b>without</b> respiratory distress or hypotension (Taylor 1989). For patients with moderate to severe symptoms, utilize the IV route (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133773'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Very limited data available: Children and Adolescents: IV, Oral: 1 mg/kg/dose; maximum dose: 50 mg/dose. May repeat every 6 to 8 hours if necessary; however, most symptoms should resolve within 6 to 8 hours after the initial dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-25876709','lexi-content-ref-27133773','lexi-content-ref-14964987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-25876709','lexi-content-ref-27133773','lexi-content-ref-14964987'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109291"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51109292"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F8082170"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9109" href="/d/html/9109.html" rel="external">see "Diphenhydramine (systemic): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Dosing recommendations are based on clinical experience and a general dosing range from manufacturer's labeling unless otherwise noted. Although oral dosing up to 50 mg every 4 hours (maximum: 300 mg/day) and parenteral dosing up to 100 mg every 6 hours (maximum: 400 mg/day) are approved in some labels, adverse effects may be increased at these higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11570937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11570937'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e4860e16-2539-4d74-8ea8-b4cb9351261e">Allergic reactions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic reactions:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Anaphylaxis (adjunct to epinephrine):</i> Note: </b>Administer epinephrine first when treating anaphylaxis. Do <b>not</b> use diphenhydramine for initial or sole treatment of anaphylaxis because H<sub>1</sub> antihistamines do <b>not</b> relieve upper or lower airway obstruction, hypotension, or shock.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 25 to 50 mg once, then every 4 to 6 hours as needed; administer after epinephrine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-Campbell.2021','lexi-content-ref-23268454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-Campbell.2021','lexi-content-ref-23268454'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Mild to moderate cutaneous reactions (eg, pruritus):</i> Note: </b>May combine with a topical or systemic glucocorticoid and/or H<sub>2</sub> antihistamine, depending on the severity and/or cause of the allergic reaction.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV:</b> 10 to 50 mg per dose every 6 hours as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d064c7e6-2375-4cda-a3b9-00cc7470df20">Angioedema, allergic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angioedema, allergic (acute) (alternative agent) (off-label use): Note:</b> Should not be used as monotherapy for angioedema with anaphylaxis; use epinephrine, prior to diphenhydramine, if anaphylaxis symptoms are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28081650','lexi-content-ref-Zuraw.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28081650','lexi-content-ref-Zuraw.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 10 to 50 mg per dose every 6 hours as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e671e1bc-7513-47b9-9549-39ccb4fdbb11">Common cold symptoms or upper airway cough syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Common cold symptoms (eg, rhinitis, rhinorrhea, sneezing) or upper airway cough syndrome:</b>
<b>Note:</b> Used in combination with a decongestant; adverse effects of monotherapy likely outweigh benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17486423','lexi-content-ref-22336807','lexi-content-ref-26615034','lexi-content-ref-16428686','lexi-content-ref-Weinberger.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17486423','lexi-content-ref-22336807','lexi-content-ref-26615034','lexi-content-ref-16428686','lexi-content-ref-Weinberger.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed (in combination with a decongestant); doses at the higher end of the dosing range may not be tolerated.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="265846fb-48a4-4d1d-b1b0-951c91e73477">Extrapyramidal symptoms, medication-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extrapyramidal symptoms (eg, dystonia and parkinsonism), medication-induced: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Anticholinergic agents are not recommended for the treatment of akathisia or tardive dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Acute treatment:</i></b>
<b>Note: </b>Parenteral administration is preferred for initial treatment of moderate to severe acute reactions (eg, dystonia). Once severe symptoms have resolved, transition to oral treatment. Duration of therapy is based on the severity of extrapyramidal symptoms (EPS) reaction, pharmacologic profile of the causative agent (eg, half-life, adverse effects) and patient risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9359953','lexi-content-ref-19955388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9359953','lexi-content-ref-19955388'])">Ref</a></span>). Some experts recommend attempting taper and discontinuation after several weeks to months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22651987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22651987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial dose:</i>
<b>IM, IV:</b> 25 to 50 mg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lavonas.2021','lexi-content-ref-Stroup.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lavonas.2021','lexi-content-ref-Stroup.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Subsequent doses:</i>
<b>Oral: </b>25 to 50 mg every 4 to 12 hours; maximum: 300 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.2021','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.2021','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Prophylaxis:</i> Note:</b> May be useful for preventing acute dystonic reactions when administering drugs with increased risk of causing such reactions (eg, haloperidol, metoclopramide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19955388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19955388'])">Ref</a></span>); however, in general, oral prophylactic use is not recommended to prevent antipsychotic-associated EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7997388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7997388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV: </b>12.5 to 50 mg prior to administration of high-risk medication; maximum: 400 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29431143','lexi-content-ref-22309235','lexi-content-ref-19955388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29431143','lexi-content-ref-22309235','lexi-content-ref-19955388'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b90818fe-3782-45a6-b8c1-7d20f52e3070">Infusion or transfusion reactions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion or transfusion reactions (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Premedication:</b></i>
<b>Note: </b>Typically administered prior to the infusion of certain medications (eg, chemotherapy agents, biologics); may be given with a glucocorticoid, acetaminophen, and/or an H<sub>2</sub> antihistamine. An optimal premedication regimen has not been identified; refer to institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Castells.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Castells.2019'])">Ref</a></span>). The routine use of premedication with diphenhydramine prior to blood transfusions to prevent febrile nonhemolytic or allergic transfusion reactions is not recommended or supported by data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17524101','lexi-content-ref-Tobian.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17524101','lexi-content-ref-Tobian.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> 25 to 50 mg given ~30 to 60 minutes prior to infusion; use of the oral route may require earlier administration (eg, ~1 to 2 hours prior to infusion) to allow for adequate concentrations at the time of infusion or potential reaction.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment: </i>Note:</b> Administer epinephrine first when treating anaphylaxis. Do <b>not</b> use diphenhydramine for initial or sole treatment of anaphylaxis because H<sub>1</sub> antihistamines do <b>not</b> relieve upper or lower airway obstruction, hypotension, or shock. Diphenhydramine should be used for symptomatic relief as an adjunct to other appropriate measures (eg, stopping the infusion, reducing the infusion rate).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> 25 to 50 mg; after 15 to 30 minutes, if symptoms persist, may repeat dose as needed. Do not exceed 100 mg within a 1-hour period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tobian.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tobian.1'])">Ref</a></span>). <b>Note: </b>With oral administration, onset of action is delayed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae3da13f-4010-4982-8591-e226cd4cf412">Insomnia, occasional</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Insomnia, occasional (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Routine use is <b>not</b> recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27998379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27998379'])">Ref</a></span>). When used, limit long-term use (&gt;4 weeks) to cases for which nonpharmacologic treatments are not available or not effective and benefits are felt to outweigh risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27136449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27136449'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 25 to 50 mg at bedtime for occasional use only.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56b6caea-ebbf-4c1e-93f2-543c99fc4e9b">Iodinated contrast media allergic-like reaction, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iodinated contrast media allergic-like reaction, prevention</b>
<b>: Note: </b>Generally reserved for patients with a prior allergic-like or unknown-type iodinated contrast reaction who will be receiving another iodinated contrast agent; use in combination with a glucocorticoid (eg, prednisone, methylprednisolone). Nonurgent premedication with oral diphenhydramine is generally preferred when contrast administration is scheduled to begin in ≥12 hours; however, consider an urgent (accelerated) regimen with IV diphenhydramine for those requiring contrast in &lt;12 hours. Efficacy of premedication regimens starting &lt;4 to 5 hours before the use of contrast has not been demonstrated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b>
<b>, IV, IM:</b> 50 mg administered 1 hour before contrast medium administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e90da07d-2e0b-4acd-8903-79bfe2dd19c5">Motion sickness</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Motion sickness: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Prophylaxis:</i></b>
<b>Oral:</b> 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed. <b>Note: </b>Antihistamines may be administered 30 to 60 minutes before motion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dramamine.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dramamine.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV:</b> 10 to 50 mg per dose every 6 hours as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fec3b37-3e64-424c-a849-4e0fe4d40b2c">Nausea and vomiting, pregnancy associated, severe or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting, pregnancy associated, severe or refractory (alternative agent) (off-label use): Note:</b> May be considered as a component of combination therapy when symptoms persist following initial pharmacologic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076'])">Ref</a></span>). Combined use with doxylamine (or other H<sub>1</sub> antagonist) may increase adverse reactions; some experts recommend discontinuation of doxylamine when initiating diphenhydramine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Smith.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Smith.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076','lexi-content-ref-Smith.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076','lexi-content-ref-Smith.2020'])">Ref</a></span>). <b>Note</b>
<b>:</b> Maximum of 100 mg per day if patient is also taking doxylamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Smith.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Smith.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 50 mg every 6 to 8 hours as needed. <b>Note:</b> Maximum of 100 mg per day if patient is also taking doxylamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Smith.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Smith.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c641946f-a396-4b5f-8d9f-53f612145141">Scombroid poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Scombroid (histamine) poisoning (off-label use):</b>
<b>Note: </b>For patients with uncomfortable symptoms (eg, flushing, burning, rash) but <b>without</b> respiratory distress or hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2689658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2689658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 25 mg every 4 to 6 hours or 50 mg every 6 to 8 hours as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 10 to 50 mg per dose every 6 hours as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f65880a4-134b-4d60-99af-28a6f3dd6eaa">Urticaria, new onset and chronic spontaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, new onset and chronic spontaneous (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Second-generation H<sub>1</sub>-antihistamines are preferred due to less sedating and anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-34536239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-34536239'])">Ref</a></span>). May consider use in combination with a second-generation H<sub>1</sub>-antihistamine in patients in whom bedtime sedating effects may be beneficial, <b>or</b> as initial parenteral therapy in patients with new-onset urticaria in whom more rapid onset of action is desired; avoid use in patients with high-risk occupations (eg, pilots, bus drivers) or who may be more prone to anticholinergic effects (eg, older adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-32707227','lexi-content-ref-Asero.1','lexi-content-ref-Khan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-32707227','lexi-content-ref-Asero.1','lexi-content-ref-Khan.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 25 to 50 mg at bedtime, <b>or</b> 25 to 50 mg 3 to 4 times per day as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV (new onset only):</b> 25 to 50 mg 3 to 4 times per day as needed; some experts administer as often as every 4 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-Asero.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-Asero.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0cafbc8a-abd9-42c0-9a5e-50ae32938929">Vertigo, acute episodes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vertigo, acute episodes (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Note: </b>Reserve use for symptomatic relief of episodes lasting several hours to days (maximum duration: 3 days); chronic use may impede adaptation and recovery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 25 to 50 mg every 4 to 6 hours as needed. Adverse effects may be increased at higher doses (eg, 300 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11570937','lexi-content-ref-32267799','lexi-content-ref-Furman.2019','lexi-content-ref-16509240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11570937','lexi-content-ref-32267799','lexi-content-ref-Furman.2019','lexi-content-ref-16509240'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> 10 to 50 mg per dose every 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Furman.2019','lexi-content-ref-16509240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Furman.2019','lexi-content-ref-16509240'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990721"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> There are no data describing diphenhydramine pharmacokinetics in kidney impairment; the following recommendations are based upon pharmacokinetic parameters only; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IM, IV, Oral: </b>No dosage adjustment necessary for any degree of kidney function (little excreted unchanged in urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis: IM, IV, Oral:</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>); no dosage adjustment or supplemental dose necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: IM, IV, Oral:</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>); no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: IM, IV, Oral:</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>); no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT: IM, IV, Oral:</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>); no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988073"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block arsc drugH1Div" id="F55765718"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic (antimuscarinic) effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Diphenhydramine may cause reversible, dose-dependent effects including <b>blurred vision</b>; <b>xerostomia</b>; <b>urinary retention</b>; impotence;<b> tachycardia</b>; gastrointestinal effects (eg, <b>nausea, constipation</b>); and CNS effects (eg, <b>agitation</b>, <b>confusion</b>, <b>cognitive dysfunction</b>, <b>delirium</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10582735','lexi-content-ref-21458946','lexi-content-ref-21963757','lexi-content-ref-17199077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10582735','lexi-content-ref-21458946','lexi-content-ref-21963757','lexi-content-ref-17199077'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; an extension of antimuscarinic pharmacological properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11570937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11570937'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21458946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21458946'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Diphenhydramine may cause CNS depression, including daytime <b>drowsiness</b>, <b>sedated state</b>, <b>fatigue</b>, <b>lack of concentration</b>, and <b>memory impairment</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728','lexi-content-ref-31062642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728','lexi-content-ref-31062642'])">Ref</a></span>). Use has been linked to <b>accidental injury</b> and fatalities due to car, plane, and boating accidents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31582993']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31582993'])">Ref</a></span>). May cause paradoxical stimulatory CNS effects including <b>irritability</b>, <b>paradoxical excitation</b>, and<b> insomnia</b>, especially in young children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17199077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17199077'])">Ref</a></span>). In overdose, infants and children often exhibit initial paradoxical CNS stimulation, including convulsions, before progressing to coma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>). In adults, CNS depression reactions, including drowsiness and coma, are most often observed in overdose situations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; crosses blood-brain barrier and blocks the neurotransmitter effect of histamine at H<sub>1</sub>-receptors in CNS, leading to significant CNS depression and toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: May occur after 1 dose. Bedtime dosing may lead to hang-over effects the following morning (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>). Conflicting evidence whether tolerance to sedation or psychomotor impairment occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting CNS disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with small body mass (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney or hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent alcohol or CNS sedative (eg, benzodiazepine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Neonates and premature infants (use is contraindicated)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F8082109"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest tightness, extrasystoles, hypotension, palpitations, tachycardia (Ochs 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, skin photosensitivity (Yamada 1998), skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, constipation, diarrhea, dry mucous membranes (Ochs 2012), epigastric discomfort, nausea, vomiting, xerostomia (Ochs 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Difficulty in micturition, early menses, urinary frequency, urinary retention (Shimizu 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, hemolytic anemia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (Mur Gimeno 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, chills, confusion (Church 2010), dizziness, drowsiness (Church 2010), euphoria, fatigue (Church 2010), headache, irritability (Simons 2007), nervousness (Simons 2007), neuritis, paradoxical excitation (Church 2010), paresthesia, restlessness, sedated state (Church 2010), seizure (Church 2010), vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor (Etzel 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Acute labyrinthitis, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion, pharyngeal edema, thickening of bronchial secretions, wheezing</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (Church 2010; Ochs 2012), cognitive dysfunction (Church 2010), delirium (Ochs 2012), drug abuse (Thomas 2009), hallucination (Church 2010), insomnia (Simons 2007), lack of concentration (Church 2010), memory impairment (Church 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (Fein 2019)</p></div>
<div class="block coi drugH1Div" id="F8082106"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to diphenhydramine, other structurally related antihistamines, or any component of the formulation; neonates or premature infants; breast-feeding</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications: Parenteral: Use as a local anesthetic</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use in children &lt;6 years, to make a child sleep, or with any other diphenhydramine-containing products (including topical products)</p></div>
<div class="block war drugH1Div" id="F8082107"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use with caution in patients with a history of asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia, bladder neck obstruction, and/or GU obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Antihistamines may cause excitation in young children. Toxicity (overdose) in pediatric patients may result in hallucinations, convulsions, or death; neonates and young children are highly sensitive to depressive effects of diphenhydramine; use is contraindicated in neonates and premature infants.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alcohol: Some oral liquid products may contain alcohol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oral liquid: Oral solutions are available in two concentrations (ie, 12.5 mg/5 mL and 50 mg/30 mL [eg, ZzzQuil]); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as "mg"; the 50 mg/30 mL oral solution is indicated for the occasional treatment of insomnia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parenteral: Subcutaneous or intradermal use has been associated with tissue necrosis; administer IV or IM only.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some products may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar, 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Soy protein: Some preparations contain soy protein; avoid use in patients with soy protein or peanut allergies.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): Do not use with other products containing diphenhydramine, even ones used on the skin. Oral products are not for OTC use in children &lt;6 years of age.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878764"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects, including death, have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients &lt;2 years of age and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018). Toxicity (overdosage) in pediatric patients can result in hallucinations, convulsions, or death. Neonates and infants are highly sensitive to depressive effects of diphenhydramine; use is contraindicated in neonates (premature and term); use with extreme caution in infants and young children.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block dosfc drugH1Div" id="F25968298"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Dicopanol FusePaq is a compounding kit for the preparation of an oral suspension.  Refer to manufacturer's labeling for compounding instructions.</p></div>
<div class="block foc drugH1Div" id="F8082201"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief: 25 mg [contains butylparaben, edetate (edta) calcium disodium, fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye), methylparaben, polysorbate 80, propylparaben, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Banophen: 25 mg [contains corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Banophen: 25 mg [DSC], 50 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Benadryl Allergy: 25 mg [dye free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diphenhist: 25 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Allergy Relief: 25 mg [contains butylparaben, corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Sleep-Aid Maximum Strength: 50 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Allergy Relief: 25 mg [contains butylparaben, corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Sleep Aid: 50 mg [gluten free; contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Sleep-Aid Max Str: 50 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ormir: 50 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pharbedryl: 25 mg, 50 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZzzQuil: 25 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Elixir, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Di-Phen: 12.5 mg/5 mL (118 mL [DSC]) [contains alcohol, usp, fd&amp;c red #40 (allura red ac dye); cinnamon-anise flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diphen: 12.5 mg/5 mL (118 mL [DSC]) [contains alcohol, usp, fd&amp;c red #40 (allura red ac dye); cinnamon-anise flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg/5 mL (5 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Childrens: 12.5 mg/5 mL (118 mL, 236 mL, 473 mL) [alcohol free, dye free; contains saccharin sodium, sodium benzoate, sorbitol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief Childrens: 12.5 mg/5 mL (118 mL, 480 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), sodium benzoate; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aurodryl Allergy Childrens: 12.5 mg/5 mL (118 mL [DSC]) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), sodium benzoate; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Benadryl Allergy Childrens: 12.5 mg/5 mL (118 mL, 236 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), sodium benzoate; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Benadryl Allergy Childrens: 12.5 mg/5 mL (118 mL) [alcohol free, dye free, sugar free; contains saccharin sodium, sodium benzoate; bubble-gum flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Allergy Relief Childrens: 12.5 mg/5 mL (118 mL, 236 mL) [dye free; contains saccharin sodium, sodium benzoate; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Geri-Dryl: 12.5 mg/5 mL (473 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Geri-Dryl: 12.5 mg/5 mL (473 mL [DSC]) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), saccharin sodium, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">M-Dryl: 12.5 mg/5 mL (120 mL, 473 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), propylene glycol, saccharin sodium, sodium benzoate; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Naramin: 12.5 mg/5 mL (5 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), sodium benzoate; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">PediaCare Childrens Allergy: 12.5 mg/5 mL (118 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">PediaClear Cough Childrens: 6.25 mg/mL (50 mL [DSC]) [contains propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Siladryl Allergy: 12.5 mg/5 mL (118 mL, 237 mL, 473 mL) [alcohol free, sugar free; contains fd&amp;c red #40 (allura red ac dye), methylparaben, propylene glycol, propylparaben, saccharin sodium; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Total Allergy Medicine: 12.5 mg/5 mL (118 mL) [alcohol free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vanamine PD: 6.25 mg/mL (30 mL [DSC]) [contains fd&amp;c blue #1 (brill blue) aluminum lake, propylene glycol, saccharin sodium, sodium benzoate, sorbitol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZzzQuil: 50 mg/30 mL (177 mL, 354 mL) [contains alcohol, usp, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), propylene glycol, saccharin sodium, sodium benzoate; berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZzzQuil: 50 mg/30 mL (354 mL [DSC]) [contains alcohol, usp, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), propylene glycol, saccharin sodium, sodium benzoate; vanilla cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZzzQuil: 50 mg/30 mL (177 mL [DSC], 354 mL [DSC]) [alcohol free; contains fd&amp;c blue #1 (brilliant blue), propylene glycol, saccharin sodium, sodium benzoate; mango berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg/5 mL (5 mL, 10 mL, 118 mL, 473 mL); 6.25 mg/mL (30 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (1 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aler-Dryl: 50 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anti-Hist Allergy: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Banophen: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Benadryl Allergy: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Benadryl Allergy Extra Str: 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Benadryl Allergy Ultratabs: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Complete Allergy Relief: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diphen: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Allergy Relief: 25 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Nighttime Sleep Aid: 25 mg [contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Geri-Dryl: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nighttime Sleep Aid: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nytol: 25 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nytol Maximum Strength: 50 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simply Sleep: 25 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sleep Tabs: 25 mg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Total Allergy: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Benadryl Allergy Childrens: 12.5 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Allergy Relief: 25 mg [contains carrageenan, fd&amp;c red #40 (allura red ac dye); mixed berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg</p></div>
<div class="block geq drugH1Div" id="F8082077"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F8082205"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Banophen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (diphenhydrAMINE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.02 - $0.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.02 - $0.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Benadryl Allergy Childrens Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $0.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (diphenhydrAMINE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $12.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Elixir</b> (diphenhydrAMINE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/5 mL (per mL): $0.18 - $0.45</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Benadryl Allergy Childrens Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/5 mL (per mL): $0.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (diphenhydrAMINE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/5 mL (per mL): $0.30 - $0.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Naramin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/5 mL (per mL): $0.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Total Allergy Medicine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/5 mL (per mL): $0.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (diphenhydrAMINE HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $0.98 - $3.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Banophen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Benadryl Allergy Extra Str Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Benadryl Allergy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Benadryl Allergy Ultratabs Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (diphenhydrAMINE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.02 - $0.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Simply Sleep Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.13</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871059"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (1 mL)</p></div>
<div class="block admp drugH1Div" id="F52614429"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer without regards to meals; when used to prevent motion sickness, first dose should be given 30 to 60 minutes prior to exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: For IV or IM administration only. Local necrosis may result with SUBQ or intradermal use. For IV administration, may administer IV push undiluted at a rate ≤25 mg/minute or further diluted as an intermittent infusion over 10 to 15 minutes.</p></div>
<div class="block adm drugH1Div" id="F8082174"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> When used to prevent motion sickness, first dose should be given 30 minutes prior to exposure. When used for occasional insomnia, dose should be given 30 minutes before bedtime.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM, IV:</b> Injection solution is for IV or deep IM administration only. For IV administration, inject at a rate ≤25 mg/minute. Local necrosis may result with SubQ or intradermal use.</p></div>
<div class="block sts drugH1Div" id="F8082128"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at room temperature of 20°C to 25°C (68°F to 77°F); protect from light and freezing. </p>
<p style="text-indent:-2em;margin-left:2em;">Oral:  Store at room temperature.  Protect capsules and tablets from moisture. Protect oral solution from freezing and light.</p></div>
<div class="block usep drugH1Div" id="F53570800"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Prescription products:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral (Liquid: 12.5 mg per 5 mL): Treatment of allergic reactions, including uncomplicated skin reactions of urticaria and angioedema, allergic conjunctivitis, and dermatographism (FDA approved in ages ≥28 days and adults); treatment of allergic reactions to blood or plasma (FDA approved in ages ≥28 days and adults); treatment and prophylaxis of motion sickness (FDA approved in ages ≥28 days and adults); management of mild parkinsonism (including drug induced) alone or in combination with other centrally acting anticholinergic agents (FDA approved in ages ≥28 days and adults); treatment of parkinsonism in patients unable to tolerate other agents (FDA approved in elderly patients); treatment of occasional insomnia (FDA approved in ages ≥12 years and adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral: Treatment of allergic reactions (FDA approved in ages ≥28 days and adults); relief of other uncomplicated acute allergic conditions, including urticaria and angioedema (FDA approved in ages ≥28 days and adults); treatment of allergic reactions to blood or plasma (FDA approved in ages ≥28 days and adults); treatment of motion sickness (FDA approved in ages ≥28 days and adults); management of mild parkinsonism (including drug induced) alone or in combination with other centrally acting anticholinergic agents (FDA approved in ages ≥28 days and adults); treatment of parkinsonism in patients unable to tolerate other agents (FDA approved in elderly patients).</p>
<p style="text-indent:-2em;margin-left:2em;">OTC products: Relief of symptoms of hay fever or other respiratory allergies (OTC products: Capsules, tablets, liquid [12.5 mg per 5 mL]: FDA approved in ages ≥6 years and adults); relief of symptoms of common cold (OTC products: Capsules and tablets: FDA approved in ages ≥6 years and adults); treatment of occasional insomnia (OTC products: Capsules, liquid [50 mg per 30 mL]: FDA approved in ages ≥12 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Approved uses for generic products may vary; consult labeling for specific information.</p></div>
<div class="block mst drugH1Div" id="F8082072"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">DiphenhydrAMINE may be confused with desipramine, dicyclomine, dimenhyDRINATE</p>
<p style="text-indent:-2em;margin-left:4em;">Benadryl may be confused with benazepril, Bentyl, Benylin, Caladryl</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Diphenhydramine (oral), a first-generation antihistamine, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic. Exposure to concurrent anticholinergic drugs also increases risk of falls, delirium, and dementia; consider total anticholinergic burden when conducting medication reviews. However, use of diphenhydramine <i>may be appropriate</i> in certain situations such as acute treatment of severe allergic reaction (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Benadryl brand name for diphenhydramine [US, Canada], but also the brand name for cetirizine [Great Britain, Philippines] and acrivastine and pseudoephedrine [Great Britain]</p>
<p style="text-indent:-2em;margin-left:4em;">Sominex brand name for diphenhydramine [US, Canada], but also the brand name for promethazine [Great Britain]; valerian [Chile]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8082113"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak)</p></div>
<div class="block dri drugH1Div" id="F8082114"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: DiphenhydrAMINE (Systemic) may enhance the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, a disulfiram-like reaction may occur and CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Ethanol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Ethanol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F8082173"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium and/or phenylalanine.</p></div>
<div class="block pri drugH1Div" id="F8082102"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Diphenhydramine crosses the placenta (Miller 2000; Parkin 1974).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of diphenhydramine during pregnancy are available (Etwel 2017; Hansen 2020; Gilboa 2014). Fetal tachycardia, respiratory depression, and possible withdrawal symptoms (diarrhea, tremors) have been observed in case reports (Abernathy 2017; Miller 2000; Parkin 1974). Diphenhydramine may have an oxytocic effect following maternal overdose (Brost 1996; Shenai 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Diphenhydramine may be used as adjunctive therapy in the management of nausea and vomiting of pregnancy when the preferred agents do not provide initial symptom improvement (ACOG 2018). Diphenhydramine injection may also be used as adjunctive therapy to treat pregnant patients with persistent headache when the initial preferred treatments are ineffective (ACOG 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Algorithms are available for the treatment of acute rhinitis and urticaria. First-generation oral antihistamines are generally not recommended for use in pregnant patients due to side effects (AAAAI/ACAAI [Dykewicz 2020]; EAACI [Zuberbier 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Some OTC products contain alcohol; use of alternative formulations in pregnancy is preferred.</p></div>
<div class="block mopp drugH1Div" id="F56100322"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Relief of symptoms, sedation, and anticholinergic effects.</p></div>
<div class="block pha drugH1Div" id="F8082131"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competes with histamine for H<sub>1</sub>-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract; anticholinergic and sedative effects are also seen</p></div>
<div class="block phk drugH1Div" id="F8082134"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Histamine-induced wheal suppression: ≤10 hours (Simons 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Histamine-induced flare suppression: ≤12 hours (Simons 1990)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Children: 22 L/kg (range: 15 to 28 L/kg); Adults: 17 L/kg (range: 13 to 20 L/kg); Elderly: 14 L/kg (range: 7 to 20 L/kg) (Blyden 1986; Simons 1990)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 98.5% (Vozeh 1988)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic n-demethylation via CYP2D6; minor demethylation via CYP1A2, 2C9 and 2C19; smaller degrees in pulmonary and renal systems; significant first-pass effect (Akutsu 2007)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 42% to 62% (Paton 1985)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children: 5 hours (range: 4 to 7 hours); Adults: 9 hours (range: 7 to 12 hours); Elderly: 13.5 hours (range: 9 to 18 hours) (Blyden 1986; Simons 1990)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~2 hours (Blyden 1986; Simons 1990)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as metabolites; &lt;4% unchanged drug) (Albert 1975; Maurer 1988)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10962013"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Amydramine-ii | Histergan | Neocoff</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Amodormin | Benadryl | Difenhidramina df | Difenhidramina larjan | Difenhidramina Northia | Difenhidramina puntanos | Fabolergic | Fada difenhidramin | Histaler | Klonadryl antialergico | Melatol difen | Nelfigen | Sleepy</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Calmaben | Dibondrin | Histaxin | Noctor</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Childrens paedamin | Sh diphenhydramine | Snuzaid | Unisom</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Didryl | Difin | Dorenta | Pedeamin | Pedilar | Pediphen | Phenadryl | Rodamin | Rymin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Azicalm | Benylin | Nuicalm | Nustasium | R Calm</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Calmaben</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Benocten | Benylin paediatric | Bonox | Coop vitality diphenhydramin | Dormyl | Nardyl Schlaf | Sleepia</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Pasifen | Somol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Diphenhydramine | Diphenhydramine hydrochloroide</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Difenhidramina | Difenhidramina clorhidrato | Difenhidramina hcl</span>;</li>
<li>
<span class="countryCode">(CR)</span> <span class="country">Costa Rica</span><span class="countrySeparator">: </span><span class="drugName">Nervessa</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Benadryl n</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Abopretten | Arbid s | Benadryl allergy extra strength | Betadorm d | Diphenhydramin | Diphenhydramin apo rot | Diphenhydramin Fair Med | Docpelin Nachtsterne | Dolestan | Dolestan forte | Dorm | Dorm Schlaftabletten | Dormigoa N | Dormocaps | Emesan | Gib Diphenhydramin | Hemodorm | Hevert-dorm | Medicon abopretten | Medpex diphenhydramin | Moradorm nachtruhe | Nervo opt n | Olidon | S 8 schlaftabletten | Schlaftabletten | Schlaftabletten diphenhydramin | Schlaftabletten elac | Sediat | Sedopretten | Sedovegan novo | Sleepia | Vivinox sleep</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Benylan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aledryl | Antalergin | Benacyma | Benadryl | Difedrin | Difenhidramina | Dormessa | Dormilong | Dormotin | Fendramin | Fendramin sueno | Fenidramin | Fenilar | Histam | Histomin | Idramin | Morfeo | Nytol | Sorenex</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Benadryl</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Benadryl n | Dimedrol | Dimedrol ubf | Dimedrolum | Nytol | Nytol 1-a-night</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Sultan</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Nytol | Sonodor</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Diphenhydramine | Diphenhydramine HCL</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Medidryl</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Benadryl p.d | Boots sleepeaze | Diphenhydramine dydrochloride | Dreemon | Histergan | Lloyd sleep aid | Lunox sleep aid | NightAid | Nightcalm | Nytol | Paxidorm</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Benadryl</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Bendol | Bendrol | Diphenamine | Diphenhydramine | Eformat diphenhydramine hydrochloride | Eytol | Na dramine | Pms diphenhydramin | Sleepeze-pm | Unisom</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Adidryl | Arcodryl | Benadryl | Delladryl | Etadryl | Otede | Sidiadryl | Sominal | Valdres</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Diphenhist | Nytol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Nytol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Franklor nf | Kuffdryl</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Alarmeen d | Alermeen d | Alermen | Alersaf | Allermine | Allerout | Awalergin | Kindiramin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Allergan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Allermin | Drewell | Hosrol t | Nytol | Restamin | Vena</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Benylin paediatric | Unised paediatric</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cooldream | Danzamin | Difectamin | Dongkoo diphenhydramine hcl | Koniza | Sleepell | Slipel | Zeromin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Allernix | Rosmylin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Benadryl n | Dimedrol | Emesan | Nytol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Benylin | Dormigoa | Nuicalm</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Allergex hay fever &amp; allergy relief | Banophen | Benadryl | Benadryl n | Dimedrol | Nytol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Nautamine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Bionaryl | Blenifen | Bonanoti | Brudifen | Difenhidramina | Difenhidramina gi | Drafen | Gelbeck | Hidrigort | Indumir | Lurispan | Nyquil z | Nytol | Tovan | Ulcoid | Unisom | Vicnite</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Benylin paediatric | Reals aid night tablets</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Benylin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Diphenhydramine | Diphenhydraminhydrochlorid glostrup | Dormutil n | Siladryl allergy</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Diphenhydramine | Unisom</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Benadryl Allergy | Cielozam | Ferlen plus | Noctamid | Samay sleep gels | Vickzzz</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alerace | Allerin ah | Allermin | Benadrex | Benadryl | Carantin | Diahist | Diplex | Dramelin | Fendryl | Histamox | Histaphen | Histazyn | Hizon diphenhydramine | Medryl | Mucomed | Nebrecon | Pharex diphenhydramine | RiteMED Diphenhydramine Hydrochloride | Soniphen | Sucrets | Zerruphen</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Allerdol | Diphenhydramine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Nodisen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alka seltzer plus allergy | Altaryl | Benadryl | Benadryl Allergy | Children's pediaclear cough | Childrens allergy | Childrens dye free diphenhydramine hcl | Complete allergy | Compoz | Di phen | Diphen elixir | Diphenhist | Diphenhydramin hcl | Diphenhydramin Hydrchloride | Diphenhydramin hydrochloride | Diphenhydramine HCL | Dormin | Geri dryl liquid allergy relief | Hydramine | Liquid allergy relief | M dryl | Nighttime sleep aid | Pharbedryl | Siladryl | Silphen | Simply sleep | Zzzquil</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Nytol noite</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Stopkof-P</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Calmaben</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Allergin | Dimedrol | Dimedrol avexima | Dimedrol ubf</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Amydramine-ii | Diphenhydramine | Dramylin Pediatric | Pms Diphenhydramine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Desentol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bendrol | Benocten | Benylin | Paxidorm</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dimidril</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Benadryl n | Calmaben</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Diphenhydramine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anadryl | Bemadrin | Benadryl | Bromhopec | Codiphen | Dibendryl | Dimed | Dimidril | Diphene | Diphenhydramine | Sedi | Tussodryl</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Benylin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Allerjin | Benadryl | Fenotral | Koklin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Benamine | Binna | Diamine | Dimine | Diphenhydramine | Diphenhydramine HCL | Goodnight | Hitus | Hon Ramin | Hydramin | Iyasumin | Menna | Nice Sleep | P.E.L | Ramin | Runesda | Suyamine | Suyoubao anlis | Vena | Venamine | Venan | Yecoan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dimedrol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Benylin paediatric</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Benadryl | Benadryl A | Klonadryl antialergico</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Antil | Benadryl | Cerylana | Difenhidramina</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Acedexphen | Naofaramin | Tusstadt</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Benylin paediatric | Betasleep | Diphenhydramine | Dph | Lennamine | Sleepeze-pm | Teens cherry</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28697105">
<a name="28697105"></a>Abernathy A, Alsina L, Greer J, Egerman R. Transient fetal tachycardia after intravenous diphenhydramine administration. <i>Obstet Gynecol</i>. 2017;130(2):374-376. doi:10.1097/AOG.0000000000002147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/28697105/pubmed" id="28697105" target="_blank">28697105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11570937">
<a name="11570937"></a>Agostini JV, Leo-Summers LS, Inouye SK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. <i>Arch Intern Med</i>. 2001;161(17):2091-2097. doi:10.1001/archinte.161.17.2091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/11570937/pubmed" id="11570937" target="_blank">11570937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17020955">
<a name="17020955"></a>Akutsu T, Kobayashi K, Sakurada K, et al. Identification of Human Cytochrome P450 Isozymes Involved in Diphenhydramine N-Demethylation. <i>Drug Metab Dispos</i>. 2007;35(1):72-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/17020955/pubmed" id="17020955" target="_blank">17020955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1159620">
<a name="1159620"></a>Albert KS, Hallmark MR, Sakmar E, et al. Pharmacokinetics of Diphenhydramine in Man. <i>J Pharmacokinet Biopharm</i>. 1975;3(3):159-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/1159620/pubmed" id="1159620" target="_blank">1159620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4020411">
<a name="4020411"></a>Allen JC, Gralla R, Reilly L, Kellick M, Young C. Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. <i>J Clin Oncol</i>. 1985;3(8):1136-1141. doi:10.1200/JCO.1985.3.8.1136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/4020411/pubmed" id="4020411" target="_blank">4020411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee on clinical practice guidelines–obstetrics. Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266076">
<a name="29266076"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy. <i>Obstet Gynecol</i>. 2018;131(1):e15-e30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/29266076/pubmed" id="29266076" target="_blank">29266076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. 2021. https://www.acr.org/Clinical-Resources/Contrast-Manual. Last accessed August 18, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22102545">
<a name="22102545"></a>Anderka M, Mitchell AA, Louik C, et al. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. <i>Birth Defects Res A Clin Mol Teratol</i>. 2012;94(1):22-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/22102545/pubmed" id="22102545" target="_blank">22102545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3982720">
<a name="3982720"></a>Aselton P, Jick H, Milunsky A, et al. First-trimester drug use and congenital disorders. <i>Obstet Gynecol</i>. 1985;65(4):451-455.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/3982720/pubmed" id="3982720" target="_blank">3982720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Asero.1">
<a name="Asero.1"></a>Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Banophen.1">
<a name="Banophen.1"></a>Banophen Children's Allergy (diphenhydramine) [prescribing information]. Livonia, MI: Major Pharmaceuticals; July 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Banophen.2">
<a name="Banophen.2"></a>Banophen (diphenhydramine) [prescribing information]. Livonia, MI: Major Pharmaceuticals; March 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32267799">
<a name="32267799"></a>Basura GJ, Adams ME, Monfared A, et al. Clinical practice guideline: Ménière's disease. <i>Otolaryngol Head Neck Surg</i>. 2020;162(2)(suppl):S1-S55. doi:10.1177/0194599820909438<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/32267799/pubmed" id="32267799" target="_blank">32267799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7556791">
<a name="7556791"></a>Becker DE. Management of Immediate Allergic Reactions. <i>Dent Clin North Am</i>. 1995;39(3):577-586.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/7556791/pubmed" id="7556791" target="_blank">7556791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benadryl.1">
<a name="Benadryl.1"></a>Benadryl (diphenhydramine) [prescribing information]. McNeil Consumer Healthcare; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benadryl.2">
<a name="Benadryl.2"></a>Benadryl Allergy Liqui-Gels (diphenhydramine) [prescribing information]. McNeil Consumer Healthcare; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benadryl.3">
<a name="Benadryl.3"></a>Benadryl Children's Allergy Liquid (diphenhydramine) [prescribing information]. McNeil Consumer Healthcare; no date.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benadryl.4">
<a name="Benadryl.4"></a>Benadryl Allergy (diphenhydramine) [prescribing information]. McNeil Consumer Healthcare; no date.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24766875">
<a name="24766875"></a>Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. <i>J Allergy Clin Immunol</i>. 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/24766875/pubmed" id="24766875" target="_blank">24766875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28248609">
<a name="28248609"></a>Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). <i>Otolaryngol Head Neck Surg</i>. 2017;156(suppl 3):S1-S47. doi:10.1177/0194599816689667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/28248609/pubmed" id="28248609" target="_blank">28248609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17486423">
<a name="17486423"></a>Björnsdóttir I, Einarson TR, Gudmundsson LS, Einarsdóttir RA. Efficacy of diphenhydramine against cough in humans: a review. <i>Pharm World Sci.</i> 2007;29(6):577-583. doi:10.1007/s11096-007-9122-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/17486423/pubmed" id="17486423" target="_blank">17486423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3760245">
<a name="3760245"></a>Blyden GT, Greenblatt DJ, Scavone JM, et al. Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous and Oral Administration. <i>J Clin Pharmacol</i>. 1986;26(7):529-533.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/3760245/pubmed" id="3760245" target="_blank">3760245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8942519">
<a name="8942519"></a>Brost BC, Scardo JA, Newman RB. Diphenhydramine overdose during pregnancy: lessons from the past. <i>Am J Obstet Gynecol</i>. 1996;175(5):1376-1377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/8942519/pubmed" id="8942519" target="_blank">8942519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31416456">
<a name="31416456"></a>Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. <i>Ital J Pediatr</i>. 2019;45(1):101. doi:10.1186/s13052-019-0695-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/31416456/pubmed" id="31416456" target="_blank">31416456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27986189">
<a name="27986189"></a>Campbell K, Rowe H, Azzam H, Lane CA. The management of nausea and vomiting of pregnancy. <i>J Obstet Gynaecol Can</i>. 2016;38(12):1127-1137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/27986189/pubmed" id="27986189" target="_blank">27986189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Campbell.2021">
<a name="Campbell.2021"></a>Campbell RL, Kelso JM. Anaphylaxis: emergency treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Castells.2019">
<a name="Castells.2019"></a>Castells MC, Matulonis UA, Horton TM. Infusion reactions to systemic chemotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17218934">
<a name="17218934"></a>Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/17218934/pubmed" id="17218934" target="_blank">17218934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention. Travel by air, land &amp; sea: motion sickness. The Yellow Book: CDC health information for international travel, 2020. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-by-air-land-sea/motion-sickness" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-by-air-land-sea/motion-sickness</a>. Last reviewed June 24, 2019. Accessed August 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8729889">
<a name="8729889"></a>Cheslik TA, Erramouspe J. Extrapyramidal symptoms following accidental ingestion of risperidone in a child. <i>Ann Pharmacother</i>. 1996;30(4):360-363. doi:10.1177/106002809603000407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/8729889/pubmed" id="8729889" target="_blank">8729889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benadryl.5">
<a name="Benadryl.5"></a>Children's Benadryl Dye-Free Allergy Liquid (diphenhydramine) [prescribing information]. McNeil Consumer Healthcare; no date.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benadryl.6">
<a name="Benadryl.6"></a>Childrens Benadryl Allergy (diphenhydramine) [prescribing information]. McNeil Consumer Healthcare; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benadryl.7">
<a name="Benadryl.7"></a>Childrens Benadryl Chewables Gels (diphenhydramine) [prescribing information]. McNeil Consumer Healthcare; April 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20146728">
<a name="20146728"></a>Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. <i>Allergy</i>. 2010;65(4):459-466. doi:10.1111/j.1398-9995.2009.02325.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/20146728/pubmed" id="20146728" target="_blank">20146728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cote.2019">
<a name="Cote.2019"></a>Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29431143">
<a name="29431143"></a>D'Souza RS, Mercogliano C, Ojukwu E, et al. Effects of prophylactic anticholinergic medications to decrease extrapyramidal side effects in patients taking acute antiemetic drugs: a systematic review and meta-analysis. <i>Emerg Med J</i>. 2018;35(5):325-331. doi:10.1136/emermed-2017-20694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/29431143/pubmed" id="29431143" target="_blank">29431143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18227744">
<a name="18227744"></a>de Leon J, Nikoloff DM. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. <i>CNS Spectr</i>. 2008;13(2):133-135. doi:10.1017/s109285290001628x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/18227744/pubmed" id="18227744" target="_blank">18227744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DelPozzoMagana.2017">
<a name="DelPozzoMagana.2017"></a>Del Pozzo-Magaña BR. Chronic urticaria in children: a review. <i>EMJ Dermatol</i>. 2017;5(1):74-82.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26615034">
<a name="26615034"></a>De Sutter AI, Saraswat A, van Driel ML. Antihistamines for the common cold. <i>Cochrane Database Syst Rev.</i> 2015;(11):CD009345. doi: 10.1002/14651858.CD009345.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/26615034/pubmed" id="26615034" target="_blank">26615034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22336807">
<a name="22336807"></a>De Sutter AI, van Driel ML, Kumar AA, Lesslar O, Skrt A. Oral antihistamine-decongestant-analgesic combinations for the common cold. <i>Cochrane Database Syst Rev.</i> 2012;(2):CD004976. doi:10.1002/14651858.CD004976.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/22336807/pubmed" id="22336807" target="_blank">22336807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22651987">
<a name="22651987"></a>Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? <i>J Psychopharmacol</i>. 2012;26(9):1167-1174. doi:10.1177/0269881112447988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/22651987/pubmed" id="22651987" target="_blank">22651987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PharmAssoc.1">
<a name="PharmAssoc.1"></a>Diphenhydramine Hydrochloride [prescribing information]. Greenville, SC: Pharmaceuticals Associates Inc; September 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WestWard.1">
<a name="WestWard.1"></a>Diphenhydramine Hydrochloride Injection [prescribing information]. Eatontown, NJ: West Ward Pharmaceuticals; May 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BD.1">
<a name="BD.1"></a>Diphenhydramine Hydrochloride Injection [prescribing information]. Franklin Lakes, NJ: BD Rx; December 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Diphenhydramine Hydrochloride Injection [prescribing information]. Lake Forest, IL: Hospira; January 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Armas.1">
<a name="Armas.1"></a>Diphenhydramine Hydrochloride injection [prescribing information]. Freehold, NJ: Armas Pharmaceuticals Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.2">
<a name="Hospira.2"></a>DiphenhydrAMINE hydrochloride injection [prescribing information]. Lake Forest, IL: Hospira; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PharmAssoc.2">
<a name="PharmAssoc.2"></a>Diphenhydramine hydrochloride solution [prescribing information]. Greenville, SC: Pharmaceutical Associates, Inc.; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PharmAssoc.3">
<a name="PharmAssoc.3"></a>Diphenhydramine hydrochloride solution [prescribing information]. Greenville, SC: Pharmaceutical Associates, Inc.; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Diphenhydramine injection [prescribing information]. Rockford, IL: Mylan Institutional LLC; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dormin.1">
<a name="Dormin.1"></a>Dormin (diphenhydramine) [prescribing information]. Cornwall, NY: Randob Labs; no date.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dramamine.1">
<a name="Dramamine.1"></a>Dramamine Original Formula (dimenhydrinate) [prescribing information]. Irvington, NY: Medtech Products Inc; February 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082. doi:10.1002/pbc.24508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24794886">
<a name="24794886"></a>Duran J, Siddique S, Cleary M. Effects of leukoreduction and premedication with acetaminophen and diphenhydramine in minimizing febrile nonhemolytic transfusion reactions and allergic transfusion reactions during and after blood product administration: a literature review with recommendations for practice. <i>J Pediatr Oncol Nurs</i>. 2014;31(4):223-229. doi:10.1177/1043454214532029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/24794886/pubmed" id="24794886" target="_blank">24794886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol</i>. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10582735">
<a name="10582735"></a>Estelle F, Simons R. H1-receptor antagonists: safety issues. <i>Ann Allergy Asthma Immunol</i>. 1999;83(5):481-488. doi:10.1016/s1081-1206(10)62855-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/10582735/pubmed" id="10582735" target="_blank">10582735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27878468">
<a name="27878468"></a>Etwel F, Faught LH, Rieder MJ, Koren G. The risk of adverse pregnancy outcome after first trimester exposure to H1 antihistamines: a systematic review and meta-analysis. <i>Drug Saf</i>. 2017;40(2):121-132. doi:10.1007/s40264-016-0479-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/27878468/pubmed" id="27878468" target="_blank">27878468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7937288">
<a name="7937288"></a>Etzel JV. Diphenhydramine-induced acute dystonia. <i>Pharmacotherapy</i>. 1994;14(4):492-496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/7937288/pubmed" id="7937288" target="_blank">7937288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31582993">
<a name="31582993"></a>Fein MN, Fischer DA, O'Keefe AW, Sussman GL. CSACI position statement: Newer generation H<sub>1</sub>-antihistamines are safer than first-generation H<sub>1</sub>-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. <i>Allergy Asthma Clin Immunol</i>. 2019;15:61. doi:10.1186/s13223-019-0375-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/31582993/pubmed" id="31582993" target="_blank">31582993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24605272">
<a name="24605272"></a>Felt BT, Chervin RD. Medications for sleep disturbances in children. <i>Neurol Clin Pract</i>. 2014;4(1):82-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/24605272/pubmed" id="24605272" target="_blank">24605272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25876709">
<a name="25876709"></a>Feng C, Teuber S, Gershwin ME. Histamine (scombroid) fish poisoning: a comprehensive review. <i>Clin Rev Allergy Immunol</i>. 2016;50(1):64-69. doi:10.1007/s12016-015-8467-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/25876709/pubmed" id="25876709" target="_blank">25876709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. Available at <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm" target="_blank">https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. Available at <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm" target="_blank">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fuhrman.2017">
<a name="Fuhrman.2017"></a>Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furman.2019">
<a name="Furman.2019"></a>Furman JM, Barton JJS. Treatment of vertigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32467512">
<a name="32467512"></a>Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg.</i> 2020;131(2):411-448. doi:10.1213/ANE.0000000000004833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/32467512/pubmed" id="32467512" target="_blank">32467512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3962845">
<a name="3962845"></a>Garnett WR. Diphenhydramine. <i>Am Pharm</i>. 1986;NS26(2):35-40. doi:10.1016/s0095-9561(16)38634-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/3962845/pubmed" id="3962845" target="_blank">3962845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25307228">
<a name="25307228"></a>Gilboa SM, Ailes EC, Rai RP, Anderson JA, Honein MA. Antihistamines and birth defects: a systematic review of the literature. <i>Expert Opin Drug Saf</i>. 2014;13(12):1667-198. doi:10.1517/14740338.2014.970164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/25307228/pubmed" id="25307228" target="_blank">25307228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27133773">
<a name="27133773"></a>Guergué-Díaz de Cerio O, Barrutia-Borque A, Gardeazabal-García J. Scombroid poisoning: a practical approach. Escombroidosis: abordaje práctico. <i>Actas Dermosifiliogr</i>. 2016;107(7):567-571. doi:10.1016/j.ad.2016.02.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/27133773/pubmed" id="27133773" target="_blank">27133773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32657014">
<a name="32657014"></a>Hansen C, Desrosiers TA, Wisniewski K, Strickland MJ, Werler MM, Gilboa SM. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011. <i>Birth Defects Res</i>. 2020;112(16):1234-1252. doi:10.1002/bdr2.1749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/32657014/pubmed" id="32657014" target="_blank">32657014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9359953">
<a name="9359953"></a>Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. <i>Am J Health Syst Pharm</i>. 1997;54(21):2461-2477. doi:10.1093/ajhp/54.21.2461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/9359953/pubmed" id="9359953" target="_blank">9359953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16428686">
<a name="16428686"></a>Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. <i>Chest</i>. 2006;129(1)(suppl):1S-23S. doi:10.1378/chest.129.1_suppl.1S<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/16428686/pubmed" id="16428686" target="_blank">16428686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, et al. Prospective Follow-Up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081650">
<a name="28081650"></a>James C, Bernstein JA. Current and future therapies for the treatment of histamine-induced angioedema. <i>Expert Opin Pharmacother.</i> 2017;18(3):253-262. doi:10.1080/14656566.2017.1282461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/28081650/pubmed" id="28081650" target="_blank">28081650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26359823">
<a name="26359823"></a>Kaar CR, Gerard JM, Nakanishi AK. The use of a pediatric migraine practice guideline in an emergency department setting. <i>Pediatr Emerg Care</i>. 2016;32(7):435-439. doi:10.1097/PEC.0000000000000525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/26359823/pubmed" id="26359823" target="_blank">26359823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22309235">
<a name="22309235"></a>Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others [published correction appears in <i>Headache</i>. 2012;52(3):527]. <i>Headache</i>. 2012;52(2):292-306. doi:10.1111/j.1526-4610.2011.02070.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/22309235/pubmed" id="22309235" target="_blank">22309235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khan.1">
<a name="Khan.1"></a>Khan DA. Chronic spontaneous urticaria: Standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2870459">
<a name="2870459"></a>Knight ME, Roberts RJ. Phenothiazine and butyrophenone intoxication in children. <i>Pediatr Clin North Am</i>. 1986;33(2):299-309. doi:10.1016/s0031-3955(16)35003-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/2870459/pubmed" id="2870459" target="_blank">2870459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30159612">
<a name="30159612"></a>Kovacic K, Sood M, Venkatesan T. Cyclic vomiting syndrome in children and adults: What Is new in 2018?. <i>Curr Gastroenterol Rep</i>. 2018;20(10):46. doi:10.1007/s11894-018-0654-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/30159612/pubmed" id="30159612" target="_blank">30159612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19955388">
<a name="19955388"></a>Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.<i> Schizophr Bull.</i> 2010;36(1):94-103. doi:10.1093/schbul/sbp130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/19955388/pubmed" id="19955388" target="_blank">19955388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lavonas.2021">
<a name="Lavonas.2021"></a>Lavonas EJ. First generation (typical) antipsychotic medication poisoning. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30076469">
<a name="30076469"></a>Li BUK. Managing cyclic vomiting syndrome in children: beyond the guidelines. <i>Eur J Pediatr</i>. 2018;177(10):1435-1442. doi:10.1007/s00431-018-3218-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/30076469/pubmed" id="30076469" target="_blank">30076469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26505932">
<a name="26505932"></a>Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol.</i> 2015;115(5):341-384. doi: 10.1016/j.anai.2015.07.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/26505932/pubmed" id="26505932" target="_blank">26505932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7712771">
<a name="7712771"></a>Lindsay CA, Williams GD, and Levin DL, "Fatal Adult Respiratory Distress Syndrome After Diphenhydramine Toxicity in a Child: A Case Report," <i>Crit Care Med</i>, 1995, 23(4):777-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/7712771/pubmed" id="7712771" target="_blank">7712771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11839657">
<a name="11839657"></a>Marina NM, Cochrane D, Harney E, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. <i>Clin Cancer Res</i>. 2002;8(2):413-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/11839657/pubmed" id="11839657" target="_blank">11839657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20556779">
<a name="20556779"></a>Martí-Carvajal AJ, Solà I, González LE, Leon de Gonzalez G, Rodriguez-Malagon N. Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. <i>Cochrane Database Syst Rev</i>. 2010;2010(6):CD007539. doi:10.1002/14651858.CD007539.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/20556779/pubmed" id="20556779" target="_blank">20556779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2902103">
<a name="2902103"></a>Maurer H and Pfleger K, "Screening Procedure for the Detection of Alkanolamine Antihistamines and Their Metabolites in Urine Using Computerized Gas Chromatography-Mass Spectrometry," <i>J Chromatogr</i>, 1988, 428(1):43-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/2902103/pubmed" id="2902103" target="_blank">2902103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33275693">
<a name="33275693"></a>McCormick M, Triulzi D. The use of premedications for platelet transfusions in pediatric patients. <i>Hematology Am Soc Hematol Educ Program</i>. 2020;2020(1):523-526. doi:10.1182/hematology.2020000165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/33275693/pubmed" id="33275693" target="_blank">33275693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16818836">
<a name="16818836"></a>Merenstein D, Diener-West M, Halbower AC, Krist A, Rubin HR. The trial of infant response to diphenhydramine: the TIRED study--a randomized, controlled, patient-oriented trial. <i>Arch Pediatr Adolesc Med</i>. 2006;160(7):707-712. doi:10.1001/archpedi.160.7.707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/16818836/pubmed" id="16818836" target="_blank">16818836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3928731">
<a name="3928731"></a>Messinis IE, Souvatzoglou A, Fais N, et al, "Histamine H1 Receptor Participation in the Control of Prolactin Secretion in Postpartum," <i>J Endocrinol Invest</i>, 1985, 8(2):143-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/3928731/pubmed" id="3928731" target="_blank">3928731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Milgrom.1">
<a name="Milgrom.1"></a>Milgrom H, Leung DYM. Allergic rhinitis. In: Kliegman RM, Stanton B, Behrman R, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Saunders; 2011:chap. 137.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11002881">
<a name="11002881"></a>Miller AA. Diphenhydramine toxicity in a newborn: a case report. <i>J Perinatol</i>. 2000;20(6):390-391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/11002881/pubmed" id="11002881" target="_blank">11002881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21721383">
<a name="21721383"></a>Mur Gimeno P, Alfaya Arias T, Iglesias Aranzazu M, Lombardero Vega M, Sastre B. Anaphylactic shock caused by antihistamines. <i>J Investig Allergol Clin Immunol</i>. 2011;21(4):321-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/21721383/pubmed" id="21721383" target="_blank">21721383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21458946">
<a name="21458946"></a>Ochs KL, Zell-Kanter M, Mycyk MB; Toxikon Consortium. Hot, blind, and mad: avoidable geriatric anticholinergic delirium. <i>Am J Emerg Med</i>. 2012;30(3):514.e1-514.e5143. doi:10.1016/j.ajem.2011.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/21458946/pubmed" id="21458946" target="_blank">21458946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17561616">
<a name="17561616"></a>Owens JA, Babcock D, Blumer J, et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary. <i>J Clin Sleep Med</i>. 2005;1(1):49-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/17561616/pubmed" id="17561616" target="_blank">17561616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31062642">
<a name="31062642"></a>Palmer RB, Reynolds KM, Banner W, et al. Adverse events associated with diphenhydramine in children, 2008-2015. <i>Clin Toxicol (Phila)</i>. 2020;58(2):99-106. doi:10.1080/15563650.2019.1609683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/31062642/pubmed" id="31062642" target="_blank">31062642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4443870">
<a name="4443870"></a>Parkin DE. Probable Benadryl withdrawal manifestations in a newborn infant. <i>J Pediatr.</i> 1974;85(4):580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/4443870/pubmed" id="4443870" target="_blank">4443870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2866055">
<a name="2866055"></a>Paton DM and Webster DR, "Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines)," <i>Clin Pharmacokinet</i>, 1985, 10(6):477-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/2866055/pubmed" id="2866055" target="_blank">2866055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28041678">
<a name="28041678"></a>Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. <i>J Allergy Clin Immunol</i>. 2017;139(3S):S1-S46. doi:10.1016/j.jaci.2016.09.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/28041678/pubmed" id="28041678" target="_blank">28041678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23115503">
<a name="23115503"></a>Pringsheim T, Doja A, Belanger S, Patten S; Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. <i>Paediatr Child Health</i>. 2011;16(9):590-598.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/23115503/pubmed" id="23115503" target="_blank">23115503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27136449">
<a name="27136449"></a>Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. <i>Ann Intern Med</i>. 2016;165(2):125-133. doi:10.7326/M15-2175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/27136449/pubmed" id="27136449" target="_blank">27136449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rindi.1951">
<a name="Rindi.1951"></a>Rindi V. La eliminazione degli antistaminici di sintesi con il latte e l'azione latto-goga de questi. <i>Riv Ital Ginecol.</i> 1951;34:147-57. As reported by LACTMED: <a href="https://www.ncbi.nlm.nih.gov/books/NBK501878/" target="_blank"> https://www.ncbi.nlm.nih.gov/books/NBK501878/</a>. Accessed February 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Russo.1976">
<a name="Russo.1976"></a>Russo RM, Guraraj VJ, Allen JE. The effectiveness of diphenhydramine HCl in pediatric sleep disorders. <i>J Clin Pharmacol</i>. 1976;16(5-6):284-288.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16115137">
<a name="16115137"></a>Sanders RP, Maddirala SD, Geiger TL, et al. Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. <i>Br J Haematol</i>. 2005;130(5):781-787. doi:10.1111/j.1365-2141.2005.05670.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/16115137/pubmed" id="16115137" target="_blank">16115137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27998379">
<a name="27998379"></a>Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. <i>J Clin Sleep Med</i>. 2017;13(2):307-349. doi:10.5664/jcsm.6470<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/27998379/pubmed" id="27998379" target="_blank">27998379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4131054">
<a name="4131054"></a>Saxen I. Letter: Cleft palate and maternal diphenhydramine intake. <i>Lancet</i>. 1974;1(7854):407-408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/4131054/pubmed" id="4131054" target="_blank">4131054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3797269">
<a name="3797269"></a>Schwartz RH, Einhorn A. PCP intoxication in seven young children. <i>Pediatr Emerg Care</i>. 1986;2(4):238-241. doi:10.1097/00006565-198612000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/3797269/pubmed" id="3797269" target="_blank">3797269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32001253">
<a name="32001253"></a>Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. <i>J Allergy Clin Immunol</i>. 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/32001253/pubmed" id="32001253" target="_blank">32001253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29277425">
<a name="29277425"></a>Shenai N, Shulman J, Gopalan P, Cheng E, Cerimele JM. Fetal outcomes in intentional over-the-counter medication overdoses in pregnancy. <i>Psychosomatics</i>. 2018;59(4):400-404. doi:10.1016/j.psym.2017.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/29277425/pubmed" id="29277425" target="_blank">29277425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24512575">
<a name="24512575"></a>Sheridan DC, Spiro DM, Meckler GD. Pediatric migraine: abortive management in the emergency department. <i>Headache</i>. 2014;54(2):235-245. doi:10.1111/head.12253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/24512575/pubmed" id="24512575" target="_blank">24512575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21963757">
<a name="21963757"></a>Shimizu T, Tokuda Y. Acute urinary retention. <i>Intern Med</i>. 2011;50(19):2255. doi:10.2169/internalmedicine.50.6080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/21963757/pubmed" id="21963757" target="_blank">21963757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24813298">
<a name="24813298"></a>Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. <i>J Am Acad Dermatol</i>. 2014;71(2):327-349. doi:10.1016/j.jaad.2014.03.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/24813298/pubmed" id="24813298" target="_blank">24813298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Silphen.1">
<a name="Silphen.1"></a>Silphen (diphenhydramine) [prescribing information]. Spring Valley, NY: Silarx Pharmaceuticals; July 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23268454">
<a name="23268454"></a>Simons FE, Ardusso LR, Bilo MB; World Allergy Organization. World Allergy Organization guidelines for the assessment and management of anaphylaxis.<i> World Allergy Organ J</i>. 2011;4(2):13-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/23268454/pubmed" id="23268454" target="_blank">23268454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17199077">
<a name="17199077"></a>Simons FE. Diphenhydramine in infants. <i>Arch Pediatr Adolesc Med</i>. 2007;161(1):105. doi:10.1001/archpedi.161.1.105-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/17199077/pubmed" id="17199077" target="_blank">17199077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26525001">
<a name="26525001"></a>Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. <i>World Allergy Organ J</i>. 2015;8(1):32. doi: 10.1186/s40413-015-0080-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/26525001/pubmed" id="26525001" target="_blank">26525001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2391399">
<a name="2391399"></a>Simons KJ, Watson WT, Martin TJ, et al, "Diphenhydramine: Pharmacokinetics and Pharmacodynamics in Elderly Adults, Young Adults, and Children," <i>J Clin Pharmacol</i>, 1990, 30(7):665-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/2391399/pubmed" id="2391399" target="_blank">2391399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smith.2020">
<a name="Smith.2020"></a>Smith JA, Fox KA, Clark S. Nausea and vomiting of pregnancy: treatment and outcome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.2021">
<a name="Stroup.2021"></a>Stroup TS. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2689658">
<a name="2689658"></a>Taylor SL, Stratton JE, Nordlee JA. Histamine poisoning (scombroid fish poisoning): an allergy-like intoxication. <i>J Toxicol Clin Toxicol.</i> 1989;27(4-5):225-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/2689658/pubmed" id="2689658" target="_blank">2689658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18308811">
<a name="18308811"></a>Thomas A, Nallur DG, Jones N, Deslandes PN. Diphenhydramine abuse and detoxification: a brief review and case report. <i>J Psychopharmacol</i>. 2009;23(1):101-105. doi:10.1177/0269881107083809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/18308811/pubmed" id="18308811" target="_blank">18308811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tobian.1">
<a name="Tobian.1"></a>Tobian A. Approach to the patient with a suspected acute transfusion reaction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17524101">
<a name="17524101"></a>Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. <i>Transfusion</i>. 2007;47(6):1089-1096. doi: 10.1111/j.1537-2995.2007.01242.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/17524101/pubmed" id="17524101" target="_blank">17524101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7997388">
<a name="7997388"></a>Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. <i>Pharmacotherapy</i>. 1994;14(5):543-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/7997388/pubmed" id="7997388" target="_blank">7997388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21296523">
<a name="21296523"></a>Trottier ED, Bailey B, Lucas N, Lortie A. Prochlorperazine in children with migraine: a look at its effectiveness and rate of akathisia. <i>Am J Emerg Med</i>. 2012;30(3):456-463. doi:10.1016/j.ajem.2010.12.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/21296523/pubmed" id="21296523" target="_blank">21296523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.1">
<a name="VADoD.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of chronic insomnia disorder and obstructive sleep apnea. <a href="https://www.healthquality.va.gov/guidelines/CD/insomnia/VADoDSleepCPGFinal508.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/CD/insomnia/VADoDSleepCPGFinal508.pdf</a>. Published October 2019. Accessed April 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3191648">
<a name="3191648"></a>Vozeh S, Schmidlin O, and Taeschner W, “Pharmacokinetic Drug Data,” <i>Clin Pharmacokinetics</i>, 1988, 15(4):254-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/3191648/pubmed" id="3191648" target="_blank">3191648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weinberger.2022">
<a name="Weinberger.2022"></a>Weinberger SE. Treatment of subacute and chronic cough in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wolfe.2018">
<a name="Wolfe.2018"></a>Wolfe J, Jones BL, Kreicbergs U, Jankovic M, eds. <i>Palliative Care in Pediatric Oncology</i>. Springer International Publishing; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14964987">
<a name="14964987"></a>Wu SF, Chen W. An outbreak of scombroid fish poisoning in a kindergarten. <i>Acta Paediatr Taiwan</i>. 2003;44(5):297-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/14964987/pubmed" id="14964987" target="_blank">14964987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wyllie.2016">
<a name="Wyllie.2016"></a>Wyllie R, ed. <i>Pediatric Gastrointestinal and Liver Disease</i>. 5th ed. Philadelphia, PA: Elsevier Saunders; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9667449">
<a name="9667449"></a>Yamada S, Tanaka M, Kawahara Y, Inada M, Ohata Y. Photoallergic contact dermatitis due to diphenhydramine hydrochloride. <i>Contact Dermatitis</i>. 1998;38(5):282. doi:10.1111/j.1600-0536.1998.tb05746.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/9667449/pubmed" id="9667449" target="_blank">9667449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34280477">
<a name="34280477"></a>Young TK, Glick AF, Yin HS, et al. Management of pediatric atopic dermatitis by primary care providers: a systematic review. <i>Acad Pediatr</i>. 2021;21(8):1318-1327. doi:10.1016/j.acap.2021.07.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/34280477/pubmed" id="34280477" target="_blank">34280477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16509240">
<a name="16509240"></a>Zajonc TP, Roland PS. Vertigo and motion sickness. Part II: pharmacologic treatment. <i>Ear Nose Throat J.</i> 2006;85(1):25-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/16509240/pubmed" id="16509240" target="_blank">16509240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29336054">
<a name="29336054"></a>Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy</i>. 2018;73(7):1393-1414. doi: 10.1111/all.13397.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/29336054/pubmed" id="29336054" target="_blank">29336054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34536239">
<a name="34536239"></a>Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy</i>. 2022;77(3):734-766. doi:10.1111/all.15090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diphenhydramine-systemic-pediatric-drug-information/abstract-text/34536239/pubmed" id="34536239" target="_blank">34536239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zuraw.2019">
<a name="Zuraw.2019"></a>Zuraw B. An overview of angioedema: Clinical features, diagnosis, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 19, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zzzquil.1">
<a name="Zzzquil.1"></a>Zzzquil Alcohol Free Nighttime Sleep-Aid (diphenhydramine) [prescribing information]. The Procter &amp; Gamble Manufacturing Co; June 2018.</div>
</li></ol></div><div id="topicVersionRevision">Topic 15970 Version 884.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
